Results 141 to 150 of about 13,289,433 (300)

Multitarget Regulatory Mechanisms and Research Advances of Plant‐Derived Bioactive Ingredients in Hypertension Prevention and Management

open access: yesPhytotherapy Research, EarlyView.
Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng   +6 more
wiley   +1 more source

Drugs for diabetes: part 5 DPP-4 inhibitors

open access: yes, 2011
The dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2 diabetes. In clinical
Fisher, Miles   +2 more
core  

Surface Energy Modification of Semi-Random P3HTT-DPP

open access: yes, 2016
Alkyl solubilizing side chains on conjugated polymers can serve as a handle for modifying polymer properties. Recently, oligo-ether and semifluoro alkyl side chains were utilized to tune the surface energy of random P3HT-based polymers without changing ...
Sangtaik Noh (1565080)   +3 more
core   +1 more source

Plant‐Derived Bioactives and PPAR Signaling in Functional Dyspepsia: Mechanistic Insights and Therapeutic Perspectives

open access: yesPhytotherapy Research, EarlyView.
Functional dyspepsia involves duodenal barrier dysfunction, low‐grade immune activation and altered neuroimmune signalling. Various plant‐derived bioactives may modulate PPAR signalling, reduce inflammatory and oxidative stress, and support epithelial, immune, metabolic, and sensory homeostasis.
Irene Palenca   +5 more
wiley   +1 more source

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice. [PDF]

open access: yesBiomedicines, 2023
Alshamrani AA   +10 more
europepmc   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

RS3PE Syndrome with Subsequent PMR Caused by Long-Term DPP-4 Inhibitor Use. [PDF]

open access: yesEur J Case Rep Intern Med, 2023
Takahashi Y   +4 more
europepmc   +1 more source

Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source‐Triangulated Counseling Map

open access: yesAndrology, EarlyView.
ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul   +3 more
wiley   +1 more source

DPP-4 Inhibitor Improved the Cognitive Function in Diabetic Rats. [PDF]

open access: yesJ Healthc Eng, 2022
Hu Y, Wang J, Wang J, Chen W, Zhang Q.
europepmc   +1 more source

Home - About - Disclaimer - Privacy